



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0199-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Pierre CHARNEAU et al.) Group Art Unit: 1645
Application No.: 10/602,663) Examiner: Unassigned
Filed: June 25, 2003)
For: USE OF TRIPLEX STRUCTURE) Confirmation No.: 8007
DNA IN TRANSFERRING)
NUCLEOTIDE SEQUENCES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were previously submitted in a prior application no. 09/688,990, filed October 17, 2000, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 4, 2004

By:


Kenneth J. Meyers
Reg. No. 25,146

JUN 04 2004
U.S. PATENT AND TRADEMARK OFFICE

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.		3495.0199-01		Serial No. 09/602,663		
Applicant		Pierre CHARNEAU et al.				
Filing Date		June 25, 2003		Group: Unassigned		
U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS						
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	WO 97/12622	4/10/97	PCT			
	WO 97/32983	9/12/97	PCT			
	WO 98/39463	9/11/98	PCT			
	0 611 822 A2	8/24/94	Europe			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Zufferey et al., Multiply attenuated lentiviral vector achieves efficient gene delivery <i>in vivo</i> ; Nature Biotechnology, Vol. 15, (1997) 871-875					
	Charneau et al., HIV-1 Reverse Transcription, A termination step at the center of the genome; J. Mol. Biol. (1994) 241, 651-662					
	Charneau et al., A single-stranded gap in human immunodeficiency virus unintegrated linear DNA defined by a central copy of the polypurine tract; J. Virol. (1991) 65, 2415-2421					
	Charneau et al., A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication; J. Virol. (1992) 66, 2814-2820					
	Erlwein et al., Sequences in <i>pol</i> are required for transfer of human foamy virus-based vectors; J. Virol. (1998) 72, 5510-5516					
	Naldini et al., Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector; Proc. Natl. Acad. Sci. USA, (1996) Vol. 93, 11382-11388					
	Naldini et al., <i>In vivo</i> gene delivery and stable transduction of nondividing cells by a lentiviral vector; Science, Vol. 272, (1996) 263-267					
	Poznansky et al., Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector; J. Virol. (1991) 65, 532-536					
	Stetor et al., Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome; Biochem. (1999) Vol. 38, 3656-3667					
	Kim et al.; Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression; J. Virol. (1989) 63, 3708-3713					

	Goldman et al.; Lentiviral vectors for gene therapy of cystic fibrosis; Human Gene Therapy (1997) 8, 2261-2268
	Search reports issued in the corresponding French and PCT applications Nos. 9805197 and PCT/FR/00974
Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce